Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese' | SpringerLink
DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8
DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts
Multiple myeloma current treatment algorithms | Blood Cancer Journal
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Recent Advances in the Treatment of Patients with Multiple Myeloma
Sequencing of myeloma therapy: Finding the right path among many standards - Rajkumar - 2021 - Hematological Oncology - Wiley Online Library
DPd against DVd for daratumumab-naïve patients with R/R multiple myeloma | VJHemOnc
Roundtable Discussion: Panelists Debate Therapy Options for R/R Multiple Myeloma With Renal Impairment
ASCO 2016 Multiple Myeloma Update – Days One, Two, And Three
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Treatment algorithm for newly diagnosed multiple myeloma and relapsed... | Download Scientific Diagram
JPM | Free Full-Text | Targeted Therapies for Multiple Myeloma
Final results from a phase III randomized study comparing DVd with VA…
Carfilzomib Twice Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and Dex
Approved for use in:
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet Oncology
![PDF] Treatment of relapsed and refractory multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5b69ac4a309afefbc2e325fbf5b369be3c2eda8f/7-Figure1-1.png "PDF] Treatment of relapsed and refractory multiple myeloma | Semantic Scholar")
PDF] Treatment of relapsed and refractory multiple myeloma | Semantic Scholar
Approval of Dvd for myeloma at first relapse in the UK: impacts on care | VJHemOnc
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Oxford Myeloma Group
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016 in: Journal of the National Comprehensive Cancer Network Volume 14 Issue 4 (2016)
IberDd Versus DVd - Multiple Myeloma Clinical Trials
